3075 – ONCOGENIC DEUBIQUITINATION CONTROLS TYROSINE KINASE SIGNALING AND THERAPY RESPONSE IN ACUTE LEUKEMIA

Qi Jin,Panagiotis Ntziachristos

DOI: https://doi.org/10.1016/j.exphem.2021.12.293

IF: 3.249

2021-08-01

Experimental Hematology

Abstract:Dysregulation of signaling kinase pathways via mutations favors tumor cell survival and response to therapy and it is common in cancer. Here, we reveal a novel post-translational regulation of kinase pathways and nuclear receptor activity via deubiquitination in acute leukemia. Driven by our previous studies showing the critical role for deubiquitination in T-cell acute lymphoblastic leukemia (T-ALL)(Jin et al., 2019; Zhou et al., 2020), we performed an unbiased analysis of deubiquitinase enzyme levels and association with T-ALL prognosis, coupled to a number of biochemical, molecular and in vivo disease modeling studies. Our characterization of gene expression and functional data for the largest deubiquitinases subfamily, ubiquitin specific peptidase (USP), in cancer patients and cell lines, demonstrated that USP11 plays oncogenic role in lymphoid malignancy and showed that it's highly expressed in high risk of T cell leukemia associated with poor prognosis. USP11 ablation inhibits leukemia growth in vitro and in vivo, sparing normal hematopoiesis and thymus development, suggesting that USP11 could be a therapeutic target in leukemia. USP11 forms a complex with USP7 to deubiquitinate oncogenic lymphocyte cell-specific protein-tyrosine kinase (LCK). Deubiquitination of LCK controls its activity, thus altering T cell receptor signaling. Attenuation of LCK or the deubiquitinase activity leads to increased expression of the glucocorticoid receptor transcript culminating in transcriptional activation of apoptotic target genes and sensitizes primary T-ALL patient samples to glucocorticoids. Taken together, our data unveil how dysregulated deubiquitination controls signaling pathways leading to cancer cell survival and drug response and suggest novel therapeutic combinations to target aggressive leukemia.

medicine, research & experimental,hematology